Biocon rises on the launch of Ogivri
Biocon rises on the launch of Ogivri

Biocon rises on the launch of Ogivri

Amir Shaikh Article rating: 5.0

 Biocon informed the bourses that the company, in partnership with Mylan NV, has rolled out Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab) in the US.

Gufic Biosciences gets patent certificate
Gufic Biosciences gets patent certificate

Gufic Biosciences gets patent certificate

Apurva Joshi Article rating: 3.3

Gufic Biosciences Limited has been given a patent certificate from the Patent Office, The Government of India, for Parenteral Formulations of Levosimendan.

Index trend and stocks in action December 03, 2019
Index trend and stocks in action December 03, 2019

Index trend and stocks in action December 03, 2019

DSIJ Intelligence-3 Article rating: 3.3

The zone of 11,970-12,000 would be a crucial support zone. For the bulls to resume its uptrend, it needs to sustain above the identical high of previous two bars, which is placed between 12,137 and 12,147 levels. Stocks in news: Biocon, RBL Bank, IFCI, United Spirits, Aurobindo Pharma, Bank of Baroda.

Brace yourself for global weakness today
Brace yourself for global weakness today

Brace yourself for global weakness today

DSIJ Intelligence-3 Article rating: 5.0

The weakness of the preceding two trading sessions is likely to exacerbate with the bears tightening their grip as the US President, Donald Trump, said that he plans to reinstate tariffs on metal imports from Brazil and Argentina. This move, most likely, would ruin previous terms with these countries and amplify a global trade war that the president had appeared ready to scale back.

IFC to invest in Mahindra & Mahindra Financial Services
IFC to invest in Mahindra & Mahindra Financial Services

IFC to invest in Mahindra & Mahindra Financial Services

DSIJ Intelligence Article rating: 5.0
Mahindra & Mahindra Financial Services Ltd. said on Monday that it has raised US$200 million (about Rs. 1,435 crores) in an investment round, anchored by International Finance Corporation (IFC).
RSS
First31643165316631673169317131723173Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR